Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2009

MMV Takes Over Merck & Co.’s Early-Stage Antimalarial

  • Merck & Co. licensed an early-stage malaria drug candidate to Medicines for Malaria Venture (MMV). The agreement allows MMV to develop and use the treatment in the developing world.

    Merck retains the option to become MMV's development partner upon completion of the first Phase II trial. As per the terms of the transaction, Merck will not profit from the drug’s use in developing countries or receive royalties.

    Preclinical safety and efficacy evaluation of the antimalarial drug candidate has been completed, and it is ready to enter clinical studies. It is an orally available compound, which could potentially provide a daily or twice-daily curative dosing regimen, according to MMV. In preclinical studies, it has shown to be effective against P. falciparum including multidrug resistant strains.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »